Clinical Trial Update: Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

View source ↗

Summary

This study is recruiting to evaluate Iruplinalkib in ALK-positive advanced non-small cell lung cancer after progression on Lorlatinib, incorporating real-world …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Iruplinalkib (iruplinalkib)

Snippet

Sponsor: Peking University Shenzhen Hospital | Conditions: Non-Small Cell Lung Cancer, ALK | Status: RECRUITING